China Deal Monitor: Denovo Biopharma raises $43m and other updates

China-based clinical stage biopharmaceutical company Denovo Biopharma has secured 300 million yuan ($43 million) in a Series B round funding round backed by Jiuyou Capital, Sangel Capital, Share Capital, Zheshang Industrial Integration, Yuexiu Industrial Fund, Qianzhan Capital and Wenfang Technology Co., Ltd, according to a media statement.